0.5786

1.47% 0.0084

After Hours: .57 -0.0086 -1.49%

Citius Pharmaceuticals Inc (CTXR)

Overview News Price History Option Chain Financials Why CTXR Down? Discussions Forecast Stock Split

Citius Pharmaceuticals Inc stock is traded at $0.5786, with a volume of 65,157. It is up +1.47% in the last 24 hours and down -4.16% over the past month. Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Previous Close:

$0.5702

Open:

$0.5702

24h Volume:

65,157

Relative Volume:

0.13

Market Cap:

$15.88M

Revenue:

$5.61M

Net Income/Loss:

$-55.45M

P/E Ratio:

-0.2251

EPS:

-2.5703

Net Cash Flow:

$-42.35M

1W Performance:

-3.57%

1M Performance:

-4.16%

6M Performance:

-19.64%

1Y Performance:

-49.69%

1-Day Range:

$0.5665

$0.5957

1-Week Range:

$0.56

$0.61

52-Week Range:

$0.4687

$2.19

Citius Pharmaceuticals Inc Stock (CTXR) Company Profile

Name

Citius Pharmaceuticals Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

(908) 967-6676

Address

11 COMMERCE DRIVE, CRANFORD, NJ

Employee

Twitter

Next Earnings Date

2026-08-18

Latest SEC Filings

CTXR's Discussions on Twitter

Compare CTXR vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CTXR Citius Pharmaceuticals Inc	0.5786	15.88M	5.61M	-55.45M	-42.35M	-2.5703
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-30-24	Upgrade	D. Boral Capital	Hold → Buy
Nov-30-21	Initiated	Maxim Group	Buy

Citius Pharmaceuticals Inc Stock (CTXR) Latest News

Sep 18, 2026

CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill

Sep 18, 2026

CTXR Stock Price, Quote & Chart - ChartMill

Sep 18, 2026

Sep 17, 2026

Citius Pharmaceuticals stock trades quietly as investors await next catalysts - ad-hoc-news.de

Sep 17, 2026

Sep 15, 2026

CTXR: LYMPHIR’s launch gains momentum with strong early adoption and expanded sales force - TradingView

Sep 15, 2026

Sep 10, 2026

Citius Pharmaceuticals at Moody Capital conference: launch gains traction By Investing.com - Investing.com UK

Sep 10, 2026

Sep 09, 2026

Citius Pharmaceuticals at Moody Capital conference: launch gains traction - Investing.com

Sep 09, 2026

CTXR: LYMPHIR launch drives early revenue and creates an investment arbitrage opportunity - TradingView

Sep 09, 2026

Sep 05, 2026

Citius Pharmaceuticals stock stabilizes as investors look to next data catalysts - ad-hoc-news.de

Sep 05, 2026

CTXR Should I Buy - Intellectia AI

Sep 05, 2026

Sep 03, 2026

Citius Pharma CEO to speak at two New York conferences - Stock Titan

Sep 03, 2026

Citius Pharmaceuticals to Participate in September 2026 Investor Conferences - PR Newswire

Sep 03, 2026

Aug 30, 2026

Citius Pharmaceuticals Inc. Warrant (CTXRW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Aug 30, 2026

Citius Pharmaceuticals Inc. Warrant (CTXRW) Key Financial Ratios – Valuation, Profitability & More - Value Research

Aug 30, 2026

Aug 28, 2026

TFIN-P Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Aug 28, 2026

Aug 27, 2026